OmniAb (OABI) Competitors

OmniAb (NASDAQ:OABI) and GoodRx (NASDAQ:GDRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.

Which has preferable valuation and earnings, OABI or GDRX?

GoodRx has higher revenue and earnings than OmniAb. GoodRx is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$34.16M	13.27	-$50.62M	-$0.62	-5.18
GoodRx	$750.27M	2.51	-$8.87M	-$0.03	-165.00

Which has more risk and volatility, OABI or GDRX?

OmniAb has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Does the media favor OABI or GDRX?

In the previous week, GoodRx had 2 more articles in the media than OmniAb. MarketBeat recorded 6 mentions for GoodRx and 4 mentions for OmniAb. GoodRx's average media sentiment score of 0.99 beat OmniAb's score of 0.97 indicating that GoodRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in OABI or GDRX?

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 8.6% of OmniAb shares are owned by insiders. Comparatively, 4.2% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend OABI or GDRX?

OmniAb currently has a consensus target price of $9.00, suggesting a potential upside of 180.37%. GoodRx has a consensus target price of $8.38, suggesting a potential upside of 69.19%. Given OmniAb's stronger consensus rating and higher probable upside, equities research analysts plainly believe OmniAb is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
GoodRx	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

Is OABI or GDRX more profitable?

GoodRx has a net margin of -2.05% compared to OmniAb's net margin of -308.78%. GoodRx's return on equity of 5.35% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-308.78%	-20.97%	-18.05%
GoodRx	-2.05%	5.35%	2.51%

Does the MarketBeat Community favor OABI or GDRX?

GoodRx received 49 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 39.56% of users gave GoodRx an outperform vote.

Company	Underperform	Outperform
OmniAb	Outperform Votes 23 100.00%	Underperform Votes No Votes
GoodRx	Outperform Votes 72 39.56%	Underperform Votes 110 60.44%

Summary

GoodRx beats OmniAb on 12 of the 19 factors compared between the two stocks.